Aura Biosciences, Inc. (AURA)
AURANASDAQ-GMBiotechnology: Biological Products (No Diagnostic Substances)
$7.11
+0.0500 (+0.71%) today
At the close, Nov 12, 4:00 PM ET. Pre-market $7.13 +0.25%
- Market cap
- $741.84m
- P/E
- –
- EPS, last 4 quarters
- $-1.64
- Dividend yield
- –
- Day range
- –
- 52-week range
- $4.73 to $9.54
- Average volume
- –
- Previous close
- $7.06
Analysts
2 coveringBuy2 buy, 0 hold, 0 sell
Targets a year out average $18.00, +153.2% from here
Earnings
next estimate $-0.2300Next report
Dec 2025
+13.9%
Mar 2026
-25.0%
Jun 2026
-17.1%
Sep 2026
+6.5%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$27.24m | -$34.87m | -$48.07m | -$35.06m |
| Net income | -$25.56m | -$33.69m | -$45.64m | -$32.07m |
News
8 latest- Here's Why You Should Add AURA Stock to Your Portfolio NowZacks · 19 hours ago
- Wall Street Analysts Believe Aura Biosciences (AURA) Could Rally 119.61%: Here's is How to TradeZacks · 1 day ago
- Aura Biosciences Reports Third Quarter 2026 Financial Results and Recent Business HighlightsFintel · 4 days ago
- Aura Biosciences Advances Phase 3 Eye Cancer Trial; Cash Runway Extends Into 2029 RTTNews · 4 days ago
- Weekly Buzz: LNTH, CBLL Win FDA Nod; AURA Cuts Jobs; TDY Buys VREX; CGEM, DFTX Meet Trial Goals RTTNews · Aug 15, 2026
- Aura Posts Wider Loss In Q2, Expects Cash Runway Into FY29; Reports Phase 1b/2 Interim Data RTTNews · Aug 11, 2026
- Top Biotech Gainers: PPCB Launches Share Buyback, VRXA Partners With ATUM, SLS On Watch RTTNews · Jul 3, 2026
- Aura Completes Enrollment In Phase 3 CoMpass Study For Bel-sar In Treating Choroidal Melanoma RTTNews · Jun 2, 2026
The company
Aura Biosciences is a clinical-stage biotechnology company developing bel-sar, a potentially transformative, first-in-class front-line vision-preserving therapy for patients living with ocular cancers. Bel-sar represents an entirely novel approach to treating ocular cancers via its dual mechanisms of action of acute tumor necrosis and secondary anti-tumor immune activation. The Phase 3 registration study of Bel-sar in early choroidal melanoma, the largest patient segment of uveal melanoma, is fully enrolled, and earlier stage studies in metastases to the choroid and cancers of the ocular surface are ongoing. Aura's mission is to improve outcomes for patients living with ocular cancers by delivering a therapy that not only arrests tumor growth but also preserves vision and quality of life.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- aurabiosciences.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.